Eikon Therapeutics
PublicEikon Therapeutics is now publicly traded
The data on this page reflects Eikon Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Feb 4, 2026
Last Round
Series D
Feb 26, 2025
Est. Valuation at Exit
$1.85B
Total Funding Raised
$1.5B
Company Overview
Eikon Therapeutics is a biotechnology company that develops small-molecule therapeutics by leveraging a proprietary single-molecule tracking platform to visualize protein dynamics in living cells.
Sector
Biotech
Verticals
Life Sciences
AI Layer
Application
Keywords
Eikon Therapeutics Comparables
Compare Eikon Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Relay Therapeutics | 86% | |
| Recursion Pharmaceuticals | 79% | |
| Insitro | 78% | |
Eikon Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Feb 4, 2026 | ||||
| Series D | Feb 26, 2025 | ||||
| Series C | Jun 1, 2023 | ||||
| Series B | Jan 6, 2022 | ||||
| Series A | May 5, 2021 | ||||
Seed | Jan 1, 2019 |
Key People
Founding team and executive leadership
Eikon Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EcoR1 Capital | Series B |
| The Column Group | Series B, Series A, Series D |
| CPP Investments | Series B |
| Horizons Ventures | Series B |
| Puccini Investments Holdings | Series A |
| Innovation Endeavors | Series B, Series A |
| E15 VC | Series D, Series B |
Eikon Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
